AA
SNTI icon

Ancora Advisors’s Senti Biosciences Holdings SNTI Stock Holding History

Ancora Advisors’s Portfolio SNTI Stock Details SNTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-300
Closed -$30K – 2503
2021
Q4 		$30K Hold
300
– – ﹤0.01% 1451
2021
Q3 		$30K Buy
+300
New +$29.6K ﹤0.01% 1346

Other funds holding SNTI

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

Ancora Advisors's SNTI Position: Q1 2022 in Review

Ancora Advisors sold out of Senti Biosciences Holdings (SNTI) in Q1 2022, closing a stake of 300 shares — an estimated $30K sold.

Ancora Advisors first reported a position in SNTI in Q3 2021 and held it in 2 quarters. The position peaked at $30K in Q4 2021. 45 funds tracked by Wall St. Rank hold SNTI as of Q1 2022.

  • Ancora Advisors reported no remaining Senti Biosciences Holdings position as of Q1 2022 after selling out during the quarter.
  • Ancora Advisors sold 300 Senti Biosciences Holdings shares in Q1 2022, an estimated $30K.
  • Ancora Advisors first reported a position in Senti Biosciences Holdings in Q3 2021 and held it in 2 quarters.
  • Ancora Advisors's Senti Biosciences Holdings position peaked at $30K in Q4 2021.
  • 45 funds tracked by Wall St. Rank held Senti Biosciences Holdings as of Q1 2022.

Based on Ancora Advisors's 13F filing for Q1 2022, filed 13 May 2022.